Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
SMARTSCORE: 3/5
Legend Biotech Corp (LEGN US)
Watchlist
Contact IR
98
Analysis
Health Care
•
China
Legend Biotech Corporation operates as a biopharmaceutical company. The Company engages in discovery and development of novel cell therapies for oncology and other indications. Legend Biotech serves customers in the State of New Jersey.
more
Watchlist
Contact IR
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Genscript Biotech
•
13 Nov 2024 05:10
StubWorld: Hanwha Corp; Genscript Biotech/Legend Biotech
Hanwha Corp appears attractive here. The pushback is that HC is thinly traded. And Genscript’s deconsolidation has minimal impact on financials...
David Blennerhassett
Follow
355 Views
Share
bullish
•
Chongqing Taiji Industry (Group) A
•
10 Nov 2024 01:27
China Healthcare Weekly (Nov.10)-Biotech Model Validation, CNPGC Need to Fulfill Commitment to Taiji
Out-licensing early-stage pipelines is the worst option. China Biotech at a critical point in verifying business models. CNPGC has other methods to...
Xinyao (Criss) Wang
Follow
433 Views
Share
bearish
•
Thematic (Sector/Industry)
•
07 Nov 2024 01:02
What Does a Trump Presidency Mean for China Healthcare?
Trump successfully elected as the US President. His reform in healthcare is to achieve the independence of US pharmaceutical supply chain and...
Xinyao (Criss) Wang
Follow
510 Views
Share
bullish
•
Thematic (Sector/Industry)
•
26 Oct 2024 23:30
APAC Healthcare Weekly (Oct 27)- Samsung Biologics, Celltrion, Astellas, Otsuka, Legend, and Zai Lab
Samsung Biologics secures largest ever contract, Celltrion announced KRW100B buyback, Astellas Pharma got label expansion approval for Vyloy,...
Tina Banerjee
Follow
604 Views
Share
bearish
•
China Traditional Chinese Medicine
•
20 Oct 2024 06:24
China Healthcare Weekly (Oct.20)-A Big Lesson from China TCM's Deal Break, “Must Option” of Biotech
The break of China TCM’s privatization deal has taught us an important lesson.Globalization is a “must option”. The “industry clearing” of...
Xinyao (Criss) Wang
Follow
765 Views
Share
First
Previous
1
2
3
4
5
6
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.55.4
x